Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

3.43
+0.26008.20%
Post-market: 3.31-0.1200-3.50%19:38 EDT
Volume:127.55K
Turnover:413.33K
Market Cap:6.30M
PE:-0.13
High:3.43
Open:3.20
Low:3.00
Close:3.17
52wk High:36.65
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.61
T/O Rate:7.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.85
PE(LYR):-0.05

Loading ...

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-generation T-cell Engager Program on Track to Initiate Clinical Trials in First Half 2027

THOMSON REUTERS
·
Jul 23

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

GlobeNewswire
·
Jul 23

HCW Biologics Resolves Disputes, Clears Miramar Property Liens

TIPRANKS
·
Jul 01

HCW Biologics - Pays in Full Amounts Owed to Eirgenix Under Settlement Agreement on May 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics - to Report Settlement of $2.8 Mln Disputed Accounts Payable in Q2 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics - B&I Contractors Files Voluntary Dismissal with Prejudice Against HCW Biologics on June 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics Says B&I Contractors Drops Florida Lien Crossclaims, Settles Dispute over USD 1.1 Million Lien

Reuters
·
Jul 01

HCW Biologics regains compliance with Nasdaq

TIPRANKS
·
Jun 30

HCW Biologics Executes 1-for-6 Reverse Stock Split

Reuters
·
Jun 30

HCW Biologics Regained Compliance with Bid Price Rule Per NASDAQ Compliance Letter

THOMSON REUTERS
·
Jun 30

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

GlobeNewswire
·
Jun 30

Hcw Biologics Inc trading halted, news pending

TIPRANKS
·
Jun 30

HCW Biologics Effects 1-for-6 Reverse Stock Split June 30

Reuters
·
Jun 26

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

THOMSON REUTERS
·
Jun 26

HCW Biologics Reports Positive Phase 1 Alopecia Trial Data

TIPRANKS
·
Jun 16

HCW Biologics announces data from first two dose cohorts of HCW9302 trial

TIPRANKS
·
Jun 16

HCW Biologics says Phase 1 trial shows hair regrowth signals for HCW9302 in alopecia areata patients

Reuters
·
Jun 16

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating Il-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

THOMSON REUTERS
·
Jun 16

HCW Biologics - All Participants in 3 Mcg/Kg Cohort Show Positive Response After Single Dose

THOMSON REUTERS
·
Jun 16

HCW Biologics - to Establish Recommended Phase 2 Dose by Year End 2026

THOMSON REUTERS
·
Jun 16